543 related articles for article (PubMed ID: 15872368)
1. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368
[No Abstract] [Full Text] [Related]
2. The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes.
Watanabe N; Kanegane H; Kinuya S; Shuke N; Yokoyama K; Kato H; Tomizawa G; Shimizu M; Funada H; Seto H
J Nucl Med; 2004 Apr; 45(4):608-11. PubMed ID: 15073256
[TBL] [Abstract][Full Text] [Related]
3. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.
Popova L; Hadjidekova V; Hadjieva T; Agova S; Vasilev I
Hell J Nucl Med; 2005; 8(1):54-7. PubMed ID: 15886755
[TBL] [Abstract][Full Text] [Related]
4. 131I dosimetry and thyroid stunning.
Gerard SK; Park HM
J Nucl Med; 2003 Dec; 44(12):2039-40; author reply 2040. PubMed ID: 14660731
[No Abstract] [Full Text] [Related]
5. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
6. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH.
Lassmann M; Hänscheid H; Reiners C; Thomas SR
J Nucl Med; 2005 May; 46(5):900-1; author reply 901. PubMed ID: 15872369
[No Abstract] [Full Text] [Related]
7. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
[TBL] [Abstract][Full Text] [Related]
8. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer.
Sgouros G
J Nucl Med; 2005 May; 46(5):899-900; author reply 901. PubMed ID: 15872367
[No Abstract] [Full Text] [Related]
9. Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective.
Clarke SE
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):430-7. PubMed ID: 20537878
[No Abstract] [Full Text] [Related]
10. [Possible sequelae of the action of radioactive iodine in man].
Il'in LA; Arkhangel'skaia GV
Med Radiol (Mosk); 1973 Aug; 18(8):66-80. PubMed ID: 4801844
[No Abstract] [Full Text] [Related]
11. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
12. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis.
Joseph LJ; Bhartiya US; Raut YS; Kand P; Hawaldar RW; Nair N
Mutat Res; 2009 Apr; 675(1-2):35-40. PubMed ID: 19386245
[TBL] [Abstract][Full Text] [Related]
13. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma.
Fard-Esfahani A; Mirshekarpour H; Fallahi B; Eftekhari M; Saghari M; Beiki D; Ansari-Gilani K; Takavar A
Clin Nucl Med; 2007 Sep; 32(9):696-9. PubMed ID: 17710021
[TBL] [Abstract][Full Text] [Related]
14. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy of thyroid autonomy.
Reiners C; Schneider P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S471-8. PubMed ID: 12192548
[TBL] [Abstract][Full Text] [Related]
16. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer.
Hernández-Jardines A; Molina B; del Castillo V; Papadakis M; Rivera T; Azorín J; Herrera LA; Yokoyama E; Frías S
Rev Invest Clin; 2010; 62(1):31-8. PubMed ID: 20415057
[TBL] [Abstract][Full Text] [Related]
17. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Al-Haj AN; Lagarde CS; Lobriguito AM
Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
[TBL] [Abstract][Full Text] [Related]
18. The sodium-iodine symporter and the proton-pump inhibitors in - related to the side effects of- the treatment of thyroid cancer with iodine-131.
Sfakianakis G; Sfakianaki E
Hell J Nucl Med; 2007; 10(1):2-5. PubMed ID: 17450241
[TBL] [Abstract][Full Text] [Related]
19. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
20. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
De Klerk JM; Oyen WJ
Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
